Latest news with #DanLevine
Yahoo
10-07-2025
- Entertainment
- Yahoo
New Night at the Museum Movie Update Reveals if Ben Stiller Will Return
A Night at the Museum reimagining is in the works, and a new report on the film from Deadline has shed some light on whether or not to expect Ben Stiller to return to it. In Deadline's new report on the film, the reimagining is said to feature a new story with 'all-new characters.' This likely means many of the stars of the original, including Stiller, won't be returning for the new iteration. Alongside Stiller, the Night at the Museum franchise has included stars like Owen Wilson, Steve Coogan, Ricky Gervais, and more. According to Deadline's report, Shawn Levy and Dan Levine will produce the new reimagining. Although the original three films in the Night at the Museum franchise starred Stiller, Wilson, Coogan, Gervais, and more, none of them returned for the 2022 animated movie Night at the Museum: Kahmunrah Rises Again. The original three Night at the Museum movie came out in 2006. Two sequels followed it, including 2009's Night at the Museum: Battle of the Smithsonian and 2014's Night at the Museum: Secret of the Tomb. The animated movie was released in 2022, with that being the last project in the franchise as of now. (Source: Deadline) The post New Night at the Museum Movie Update Reveals if Ben Stiller Will Return appeared first on - Movie Trailers, TV & Streaming News, and More.
Gizmodo
10-07-2025
- Entertainment
- Gizmodo
‘Night at the Museum' Franchise Gets Reboot at Disney 20 Years After the First Film
The Night at the Museum film franchise is getting another go at 20th Century Studios under Disney to mine more historical hijinks. It's been 20 years (a shocking number, yes) since the release of the first film starring Ben Stiller (Severance) as a museum night watch guard who goes on adventures when the exhibits come to life at night. The concept spawned several sequels, which featured stars like Robin Williams, Owen Wilson, Rami Malek, and Dan Stevens as legendary figures. Deadline reports that the reboot is being produced by 21 Laps' Dan Levine and Shawn Levy (Deadpool & Wolverine), who helmed the previous iteration of the franchise. Writer Tripper Clancy (Die Hart) has been tapped as the reboot's scribe. There's no word yet if Levy will take the filmmaking reins again, but it was specified that the new movies will take place in a new museum with new characters. It would be fun to see Stiller possibly make a return as a director instead of a star. It's interesting to note the Disney connection here; over the years while the franchise went on, Disney and Jon Favreau had Magic Kingdom, a similar concept, in the works with Disney Parks as the museum stand-in. It was floated that the ride characters would come to life after dark. But now with both universes in the Mouse House, perhaps the Disneyland version of the concept could become an official spin-off to this planned Night at the Museum reboot. Follow me here: the Imagineering arm of the parks industry, for example, has made historical figures into animatronics and will be adding one based on Walt Disney himself come Disneyland's 70th birthday, right? So maybe this time around, instead of these figures coming to life because of pure magic, perhaps the figures in the museum exhibits might be animatronics-based. It would be really unhinged to go with that thread and make this some sci-fi fare. Then we'd really want Stiller to come back and direct. Want more io9 news? Check out when to expect the latest Marvel, Star Wars, and Star Trek releases, what's next for the DC Universe on film and TV, and everything you need to know about the future of Doctor Who.
Yahoo
06-05-2025
- Business
- Yahoo
US FDA names agency critic Vinay Prasad as top vaccine official
By Dan Levine and Julie Steenhuysen (Reuters) -The U.S. Food and Drug Administration has named Vinay Prasad, an oncologist who has previously criticized FDA leadership and COVID-19 mandates, as the director of its Center for Biologics Evaluation and Research, the agency said on Tuesday. In that role, Prasad, a frequent critic of the pharmaceutical industry, will oversee the regulation of costly and complicated biologic drugs, including vaccines, gene therapies, and blood supply. He succeeds Peter Marks, who oversaw the approval of COVID-19 vaccines and was pushed out of the agency in March. Drug company stocks fell on the news, led by an 11% drop in vaccine maker Moderna and a 20% fall in shares of smaller gene therapy developers. In a recent blog post on the Substack platform, Prasad said the CDC "should ABSOLUTELY remove COVID-19 from the Childhood Immunization schedule. If it stays, it shows the United States is a corrupt country," citing the lack of randomized trial evidence for use of the vaccines in children. In another post, Prasad criticized media coverage of Marks' departure and called him "one of the most dangerous, pro-pharma regulators of the 21st century." In a note to clients, RBC Capital Markets analyst Brian Abrahams called Prasad an "anti-establishment physician" who has been vocal on a broad range of matters, "including COVID-19, oncology studies, and randomized clinical trial designs in general." Abrahams noted that Prasad has been particularly critical of Marks' support of Sarepta Therapeutics' gene therapy treatment for Duchenne muscular dystrophy. Pfizer shares fell 3%. Smaller gene therapy developers such as Sarepta and Taysha Gene Therapies plunged about 20%. A basket of biotech shares, the SPDR S&P biotech ETF, fell 6%. It has fallen about 9% since Robert F. Kennedy Jr., a vaccine critic, was confirmed as U.S. health secretary in February. Prasad is not without supporters, however. The FDA's commissioner, Marty Makary, announced Prasad's appointment in an email to staff. 'He brings a great set of skills, energy, and competence to the FDA, and I know that he is eager to begin immersing himself in the important work of CBER and the agency as a whole,' Makary wrote. Walid Gellad, a physician from the University of Pittsburgh, said Prasad is "a brilliant guy with remarkable experience understanding evidence and data on drugs. He has a difficult task ahead but an opportunity to bring those talents to positively impact FDA and the American public." Scott Steele had been serving as acting head of CBER. Prasad comes to the FDA from the University of California, San Francisco. He holds a medical degree from the University of Chicago, and has had stints at the National Cancer Institute and the National Institutes of Health. (Reporting by Dan Levine in San Francisco, Manas Mishra and Sneha S K in Bengaluru, Julie Steenhuysen in Chicago, Michael Erman in New York; Editing by Shailesh Kuber, Emelia Sithole-Matarise and Rod Nickel)
Yahoo
28-04-2025
- Politics
- Yahoo
Democratic senators question US Justice Department on civil rights changes
By Dan Levine and Sarah N. Lynch WASHINGTON (Reuters) - Seven Democratic senators are asking the U.S. Justice Department for information about changes to its civil rights division made by President Donald Trump's administration including reassigning several career officials who had held leadership positions. The senators, all members of the U.S. Senate Judiciary Committee, wrote a letter dated on Friday to top Justice Department officials citing several recent moves that the lawmakers said appeared to change the division's enforcement objectives. "Taken together, these measures appear to be an attempt to cajole career officials at the division to leave voluntarily in order to fundamentally transform its work," the senators wrote, asking for an accounting of all personnel changes that have occurred in the division since Trump returned to office in January. The senators signing the letter were Dick Durbin, Peter Welch, Mazie Hirono, Sheldon Whitehouse, Adam Schiff, Cory Booker and Alex Padilla. A Justice Department spokesperson did not immediately respond to a request for comment. Founded in 1957 following the passage of the Civil Rights Act, the division initially focused on protecting the voting rights of Black Americans. Over the following decades, Congress expanded its responsibilities to include protecting Americans from discrimination on the basis of race, sex, disability, gender identity and other characteristics. Since Trump began his second term as president and appointed Pam Bondi as U.S. attorney general, the division has paused investigations of alleged police abuse and launched its first investigation into whether Los Angeles violated gun rights laws. Following Trump's lead, the department also changed its stance on transgender rights and investigated alleged antisemitism at U.S. colleges involving pro-Palestinian protesters. The Justice Department last week took steps to reassign about a dozen senior career attorneys from the unit, including those who managed offices that investigate local police and handled violations of voting and disability rights. "The division relies on the abilities and knowledge of its career staff to carry out the great responsibility of enforcing the nation's civil rights laws without regard to politics," the senators wrote.
Yahoo
24-04-2025
- Business
- Yahoo
Ozempic copies restricted after US judge denies injunction
By Patrick Wingrove and Dan Levine (Reuters) -A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes and weight-loss drugs Ozempic and Wegovy while a legal challenge over drug shortages unfolds, court records show. The decision came in response to a February lawsuit from a compounding industry group against the U.S. Food and Drug Administration's decision that there was no longer a shortage of the medicines' active ingredient, semaglutide. Compounders had been allowed to produce hundreds of thousands of doses of copies of Novo's obesity and diabetes drugs only while the FDA said they were in short supply. Many of these are sold by large telehealth companies like Hims & Hers. U.S. District Judge Mark Pittman in Texas denied compounders' bid for a preliminary injunction, according to the court docket. Pittman filed his legal reasoning under seal, but by denying the injunction request, a May timeline set by the FDA for when large U.S. compounders will have to exit the market remains in place. It also follows a decision the judge made earlier this year refusing to allow compounding pharmacies to keep making copies of Eli Lilly's weight-loss and diabetes drugs Zepbound and Mounjaro. The FDA and Novo Nordisk did not immediately respond to requests for comment. Lee Rosebush, chairman of lead plaintiff Outsourcing Facilities Association, told Reuters that his organization had presented evidence of an ongoing semaglutide shortage that was obtained after the lawsuit was filed. However, Rosebush said the judge declined to consider it, finding that it was filed late. The FDA had said it would not take any enforcement action against compounders before the court ruled. The regulator has given larger so-called outsourcing facilities, which make compounded drugs in bulk and are regulated by the agency, until May 22. Smaller compounding pharmacies, which make drugs to fill prescriptions for individual patients and are primarily overseen by U.S. states, must immediately cease making copies of semaglutide.
